AR047948A1 - Formulaciuones de inhibidores de la fosfodiesterasa v - Google Patents
Formulaciuones de inhibidores de la fosfodiesterasa vInfo
- Publication number
- AR047948A1 AR047948A1 ARP040104262A ARP040104262A AR047948A1 AR 047948 A1 AR047948 A1 AR 047948A1 AR P040104262 A ARP040104262 A AR P040104262A AR P040104262 A ARP040104262 A AR P040104262A AR 047948 A1 AR047948 A1 AR 047948A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- formulations
- phosphodiesterase
- active ingredient
- high energy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/14—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2202/00—Metallic substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2258/00—Small objects (e.g. screws)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Formulaciones de inhibidores de la fosfodiesterasa V farmacéuticamente aceptables que son utiles para el tratamiento de la disfuncion eréctil en el hombre y sexual en la mujer y otros trastornos fisiologicos. Reivindicacion 1: Una composicion farmacéutica que comprende una dispersion de alta energía sustancialmente amorfa, done dicha dispersion de alta energía comprende: un ingrediente farmacéuticamente activo representado por la formula estructural (1) mezclado con una matriz polimérica que comprende un vehículo polimérico y un agente humectante, donde la relacion del ingrediente farmacéuticamente activo a la matriz polimérica es de aproximadamente 1:1 a aproximadamente 1:10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52473103P | 2003-11-21 | 2003-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047948A1 true AR047948A1 (es) | 2006-03-15 |
Family
ID=34632926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104262A AR047948A1 (es) | 2003-11-21 | 2004-11-18 | Formulaciuones de inhibidores de la fosfodiesterasa v |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060040962A1 (es) |
EP (1) | EP1691788A2 (es) |
JP (1) | JP2007512345A (es) |
KR (1) | KR20060101762A (es) |
CN (1) | CN1905860A (es) |
AR (1) | AR047948A1 (es) |
AU (1) | AU2004292991A1 (es) |
BR (1) | BRPI0416202A (es) |
CA (1) | CA2546248A1 (es) |
MX (1) | MXPA06005681A (es) |
NO (1) | NO20062883L (es) |
PE (1) | PE20050985A1 (es) |
TW (1) | TW200526664A (es) |
WO (1) | WO2005051368A2 (es) |
ZA (1) | ZA200604025B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008000087A (es) * | 2005-06-23 | 2008-03-18 | Schering Corp | Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5. |
CN101516339B (zh) | 2006-08-16 | 2012-06-13 | 诺瓦提斯公司 | 制备高度结晶的治疗化合物的固体分散体的方法 |
CN101854913A (zh) * | 2007-11-12 | 2010-10-06 | 诺瓦提斯公司 | 含有缬沙坦的液体组合物 |
ITMI20080227A1 (it) * | 2008-02-13 | 2009-08-14 | Felice Vinati | '' dispositivo di sicurezza per apparati di sollevamento a fune '' |
JP6002562B2 (ja) * | 2012-12-05 | 2016-10-05 | 横浜ゴム株式会社 | 面ファスナー付き空気入りタイヤ及びその製造方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057628A (en) * | 1976-04-19 | 1977-11-08 | William L. Wilson | Removal of hepatitis associated antigen from plasma |
US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
NZ238609A (en) * | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
ATE194345T1 (de) * | 1990-12-21 | 2000-07-15 | Beecham Group Plc | Xanthinderivate |
EP0686157A1 (en) * | 1993-02-26 | 1995-12-13 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US5470479A (en) * | 1994-06-23 | 1995-11-28 | Westinghouse Electric Corporation | Continuous, steady-state, chromatographic separation of gadolinium isotopes |
EP2295436A1 (de) * | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
JP3290970B2 (ja) * | 1998-07-22 | 2002-06-10 | 山之内製薬株式会社 | 難溶性NSAIDs含有固形製剤 |
US20030153623A1 (en) * | 1998-07-22 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | Solid preparation containing sparingly soluble NSAIDs |
US6025362A (en) * | 1998-08-31 | 2000-02-15 | Fukunaga; Atsuo F. | Uses of xanthine compounds |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
US6491950B1 (en) * | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
JP3470096B2 (ja) * | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | ニルバジピン含有易溶性固形製剤およびその製造法 |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
DE60226615D1 (es) * | 2001-08-28 | 2008-06-26 | Schering Corp | |
WO2003042216A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
EP1575478A2 (en) * | 2001-12-28 | 2005-09-21 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
AR040233A1 (es) * | 2002-05-31 | 2005-03-23 | Schering Corp | Polimorfos inhibidores de xantina fosfodiesterasa v |
EP1509525B9 (en) * | 2002-05-31 | 2007-10-31 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
US7659305B2 (en) * | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
-
2004
- 2004-11-18 AR ARP040104262A patent/AR047948A1/es not_active Application Discontinuation
- 2004-11-18 KR KR1020067009586A patent/KR20060101762A/ko not_active Application Discontinuation
- 2004-11-18 MX MXPA06005681A patent/MXPA06005681A/es active IP Right Grant
- 2004-11-18 JP JP2006541424A patent/JP2007512345A/ja active Pending
- 2004-11-18 TW TW093135475A patent/TW200526664A/zh unknown
- 2004-11-18 CA CA002546248A patent/CA2546248A1/en not_active Abandoned
- 2004-11-18 WO PCT/US2004/038887 patent/WO2005051368A2/en active Application Filing
- 2004-11-18 CN CNA200480040545XA patent/CN1905860A/zh active Pending
- 2004-11-18 AU AU2004292991A patent/AU2004292991A1/en not_active Abandoned
- 2004-11-18 PE PE2004001130A patent/PE20050985A1/es not_active Application Discontinuation
- 2004-11-18 BR BRPI0416202-1A patent/BRPI0416202A/pt not_active IP Right Cessation
- 2004-11-18 EP EP04811583A patent/EP1691788A2/en not_active Ceased
- 2004-11-19 US US10/993,744 patent/US20060040962A1/en not_active Abandoned
-
2006
- 2006-05-18 ZA ZA200604025A patent/ZA200604025B/en unknown
- 2006-06-20 NO NO20062883A patent/NO20062883L/no not_active Application Discontinuation
-
2008
- 2008-11-18 US US12/272,913 patent/US20090074869A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20062883L (no) | 2006-08-18 |
JP2007512345A (ja) | 2007-05-17 |
WO2005051368A3 (en) | 2006-03-09 |
US20060040962A1 (en) | 2006-02-23 |
CA2546248A1 (en) | 2005-06-09 |
EP1691788A2 (en) | 2006-08-23 |
TW200526664A (en) | 2005-08-16 |
CN1905860A (zh) | 2007-01-31 |
AU2004292991A1 (en) | 2005-06-09 |
BRPI0416202A (pt) | 2006-12-26 |
US20090074869A1 (en) | 2009-03-19 |
MXPA06005681A (es) | 2006-08-17 |
WO2005051368A2 (en) | 2005-06-09 |
ZA200604025B (en) | 2008-01-30 |
KR20060101762A (ko) | 2006-09-26 |
PE20050985A1 (es) | 2005-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111679A2 (es) | Formulación farmacéutica de liberación controlada, procesos, usos, método | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
PE20050775A1 (es) | Formulaciones que comprenden multiparticulas de liberacion controlada | |
HUP0101543A2 (hu) | Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények | |
HRP20040479B1 (en) | Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility | |
WO2002041883A3 (en) | As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation | |
EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
AR082579A2 (es) | Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad | |
ES2055677T1 (es) | Procedimiento de obtencion de una composicion para el tratamiento de la disfuncion erectil. | |
AR048017A1 (es) | Composicion y metodo para aumentar la biodisponibilidad | |
EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
CY1106227T1 (el) | Συνθεση για τη διευκολυνση του ανθρωπινου τοκετου | |
KR20050119135A (ko) | 조루증 치료용 조성물 및 치료 방법 | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
AR047948A1 (es) | Formulaciuones de inhibidores de la fosfodiesterasa v | |
PE20050443A1 (es) | Formulaciones farmaceuticas transdermicas | |
BRPI0409571A (pt) | métodos e kits para a manutenção de gravidez, tratamento de cistos foliculares, e sincronização da ovulação empregando-se hormÈnio de luteinização | |
KR20050119134A (ko) | 발기 부전 치료용 프로스타글란딘 조성물 | |
ECSP045210A (es) | 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco | |
AR045178A1 (es) | Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica | |
CA2431519A1 (en) | Topical composition and method for treating urinary stress incontinence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |